Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending October 2013. The report details a specific share repurchase transaction executed on October 14, 2013, in accordance with shareholder authority granted at the Annual General Meeting on May 1, 2013.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 1,443,000 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,566 pence per share; lowest price paid was 1,550 pence per share.
- Treasury Holdings (Settled): 494,468,912 shares (9.21% of total issued share capital).
- Treasury Holdings (Including Unsettled): 498,810,912 shares (10.24% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,871,774,182 shares.
Material Changes
The primary material change is the reduction of outstanding shares through the purchase of 1,443,000 shares for Treasury. Consequently, the percentage of total voting rights held in Treasury increased to 10.24% when including unsettled transactions.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance announcement confirming conformity with the Financial Conduct Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (494,468,912 settled) against the company's latest capitalization table.
- Confirm the denominator for voting rights calculations is 4,871,774,182 shares (excluding Treasury).
- Check if the 10.24% Treasury holding (including unsettled) impacts any shareholder notification thresholds under Disclosure and Transparency Rules.
- Note that this filing does not contain operational or financial performance data for the period.